Proteomics Analysis for Finding Serum Markers of Ovarian Cancer

Cheng, Yu‐Shan; Liu, Chongdong; Zhang, Nawei; Wang, Shengdian; Zhang, Zhenyu

doi:10.1155/2014/179040

Cited by 38 publications

(33 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have showed that RBP4 has a role in some types of cancers such as lung[35], pancreatic[36], ovarian[25], squamous cell[26], colorectal[24], prostate cancer[23] and hepatocellular carcinoma[27]. For example, Hisanori Uehara et al[23] showed that RBP4 expression is increased in prostate cancer cells and associated with prostate cancer cell growth in vitro study.…”

Section: Discussionmentioning

confidence: 99%

“…Wang et al observed the over expression of RBP4 protein in HCC cell lines compared to normal livers (P < 0.001), which correlated with metastatic potential[27]. In addition, Cheng et al[25] indicated RBP4 expression levels in normal ovarian tissue and plasma of healthy individuals were lower than those in ovarian cancer tissues and plasma of ovarian cancer patients. Moreover, Patz et al [35] and Chen et al[26] suggested RBP4 might be used as a biomarker for the diagnosis of lung cancer and oral squamous cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…Regarding the relationship between serum RBP4 levels and cancer, Uehara et al[23] reported that RBP4 was associated with prostate cancer cell growth in vitro and increased in prostate cancer cells. In addition, epidemiological study showed that higher circulating levels of RBP4 are associated with colon adenoma[24], ovarian cancer[25] and oral squamous cell cancer[26]. Moreover, Wang et al [27] also found that RBP4 protein is correlated with overall survival of patients with hepatocellular carcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Elevated Serum Levels of Retinol-Binding Protein 4 Are Associated with Breast Cancer Risk: A Case-Control Study

Jiao

Cui

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

BackgroundRetinol binding protein 4 (RBP4) is a recently identified adipokine that is elevated in patients with obesity or type 2 diabetes. A growing body of research has shown that RBP4 is associated with several types of cancer. However, no studies have investigated the relationship between serum RBP4 levels and breast cancer risk. We performed a case-control study to evaluate the association between serum RBP4 levels and the risk of breast cancer.MethodsFrom August 2012 to December 2013, four-hundred subjects including 200 patients diagnosed with primary breast cancer and 200 matched healthy women were consecutively enrolled from Affiliated Hospital of Qingdao University Medical College. Blood samples were collected from healthy controls and breast cancer patients before commencement of treatment. Enzyme-linked immunosorbent assay was used to evaluate the serum RBP4 levels in separated serum samples. Meanwhile, the characteristics of breast cancer cases and controls were collected from medical records and pathological data.ResultsThe serum levels of RBP4 were significantly higher in patients with breast cancer than that in the healthy control group (33.77±9.92 vs. 28.77±6.47μg/ml, P < 0.05). Compared to the subjects in the lowest quartile of serum RBP4 level, the adjusted ORs (95% CIs) is 2.16(1.01–4.61) and 2.07 (1.07–4.00) for women in the second and highest RBP4 tertile, respectively. For breast cancer patients, patients with PR or ER negative displayed significantly higher serum RBP4 levels than those with PR or ER positive.ConclusionOur results for the first time suggested serum RBP4 levels could be associated with the risk of breast cancer. However, further prospective studies are essential to confirm these observed results.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated Serum Levels of Retinol-Binding Protein 4 Are Associated with Breast Cancer Risk: A Case-Control Study

Jiao

Cui

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…For instance, Fei et al reported lower RBP4 serum levels in patients with colon cancer than in healthy individuals [17]; on the other hand, Karunanithi et al and Abola et alhave shown that elevated RBP4 is associated with colon cancer progression and liver metastasis [18,19]. There are also studies showing the importance of this protein in ovarian, renal, hepatocellular, oral squamous cell, and pancreatic cancer patients [20][21][22][23][24]. Such analyses conducted in patients with breast cancer suggested a link between elevated RBP4 and the risk of breast cancer [25].…”

mentioning

confidence: 99%

Retinol-Binding Protein 4 Accelerates Metastatic Spread and Increases Impairment of Blood Flow in Mouse Mammary Gland Tumors

Papiernik

Urbaniak

Kłopotowska

et al. 2020

Cancers

View full text Add to dashboard Cite

Retinol-binding protein 4 (RBP4) is proposed as an adipokine that links obesity and cancer. We analyzed the role of RBP4 in metastasis of breast cancer in patients and in mice bearing metastatic 4T1 and nonmetastatic 67NR mammary gland cancer. We compared the metastatic and angiogenic potential of these cells transduced with Rbp4 (4T1/RBP4 and 67NR/RBP4 cell lines). Higher plasma levels of RBP4 were observed in breast cancer patients with metastatic tumors than in healthy donors and patients with nonmetastatic cancer. Increased levels of RBP4 were observed in plasma, tumor tissue, liver, and abdominal fat. Moreover, the blood vessel network was highly impaired in mice bearing 4T1 as compared to 67NR tumors. RBP4 transductants showed further impairment of blood flow and increased metastatic potential. Exogenous RBP4 increased lung settlement by 67NR and 4T1 cells. In vitro studies showed increased invasive and clonogenic potential of cancer cells treated with or overexpressing RBP4. This effect is not dependent on STAT3 phosphorylation. RBP4 enhances the metastatic potential of breast cancer tumors through a direct effect on cancer cells and through increased endothelial dysfunction and impairment of blood vessels within the tumor.Cancers 2020, 12, 623 2 of 21 cancer pulmonary metastasis. These processes precede the onset of a phenotypic switch in the lung endothelium toward a mesenchymal phenotype (EndMT), which is parallel to the appearance of the first pulmonary metastatic colonies [7]. Therefore, therapeutic strategies that aim to normalize endothelial dysfunction can decrease the metastatic potential of this type of breast cancer [8][9][10].Apart from its involvement in cancer development, endothelial dysfunction plays an important role in the development of cardiovascular diseases and atherosclerosis. Moreover, in type 2 diabetes mellitus, endothelial dysfunction and insulin resistance often coexist at the earliest stage of atherosclerosis with elevation of serum retinol-binding protein 4 (RBP4), a specific retinol transporter in the blood [11]. It is documented that RBP4 induces inflammation of endothelial cells in vitro. This action is due to the stimulation of proinflammatory molecules involved in leukocyte recruitment and their adherence to endothelium, and it is independent of retinol and the RBP4 membrane receptor STRA6 [12]. Endothelial inflammation induced by RBP4 is largely mediated by toll-like receptor 4 (TLR4), and in part, through the c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) signaling pathways [13]. Moreover, in isolated aorta rings, RBP4 treatment significantly increased NO production, stimulating the PI3K/Akt/eNOS pathway [14].RBP4, classified as adipokine [15], is proposed as the protein linking obesity and cancer [16]. Studies have shown various correlations between RBP4 plasma/tumor tissue levels and the development of certain types of cancer. For instance, Fei et al. reported lower RBP4 serum levels in patients with colon cancer than in healthy individu...

show abstract

“…Proteomic analyses identified 1200 serum proteins, among which 57 were upregulated in the sera collected from cancer patients. Retinol binding protein 4 (RBP4), which is an adipokine secreted by adipose tissue and liver, was found to be highly elevated in sera of OvCa patients compared to healthy individuals [21]. These examples suggest that proteomics profiles of OvCa patients’ sera are distinct from those of sera of healthy controls.…”

Section: Emerging Serum Biomarkersmentioning

confidence: 99%

Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma

Szajnik

Czystowska-Kuźmicz

Elishaev

et al. 2016

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Introduction Ovarian cancer (OvCa) is among the most common types of cancer and is the leading cause of death from gynecological malignancies in western countries. Cancer biomarkers have a potential for improving the management of OvCa patients at every point from screening and detection, diagnosis, prognosis, follow up, response to therapy and outcome. Areas covered The literature search has indicated a number of candidate biomarkers have recently emerged that could facilitate the molecular definition of OvCa, providing information about prognosis and predicting response to therapy. These potentially promising biomarkers include immune cells and their products, tumor-derived exosomes, nucleic acids and epigenetic biomarkers. Expert commentary Although most of the biomarkers available today require prospective validation, the development of noninvasive liquid biopsy-based monitoring promises to improve their utility for evaluations of prognosis, response to therapy and outcome in OvCa.

show abstract

Proteomics Analysis for Finding Serum Markers of Ovarian Cancer

Cited by 38 publications

References 35 publications

Elevated Serum Levels of Retinol-Binding Protein 4 Are Associated with Breast Cancer Risk: A Case-Control Study

Elevated Serum Levels of Retinol-Binding Protein 4 Are Associated with Breast Cancer Risk: A Case-Control Study

Retinol-Binding Protein 4 Accelerates Metastatic Spread and Increases Impairment of Blood Flow in Mouse Mammary Gland Tumors

Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma

Contact Info

Product

Resources

About